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Introduction
Graft-versus-host disease (GVHD) is a proinflammatory syndrome 
that is initiated by donor T cells and is the major complication of allo-
geneic hematopoietic stem cell transplantation (1–3). The overpro-
duction of inflammatory cytokines is a critical component of this pro-
cess and is able to mediate pathological damage directly, or indirectly 
by activation and/or recruitment of other effector cell populations 
(4–6). During the acute phase, GVHD generally targets a restricted 
set of organs, which include the skin, liver, and gastrointestinal (GI) 
tract. Of these tissues sites, the GI tract is of particular relevance in 
the pathophysiology of this disorder, as damage to this organ plays 
a crucial role in the amplification of systemic GVHD severity (3, 7). 
This is attributable to breakdown of the mucosal barrier, which leads 
to increased systemic proinflammatory cytokine secretion arising 
from interactions between bacterial products (e.g., endotoxin) and 
donor-derived immune effector cells that are resident in the GI tract 
(8). Clinically, this damaged mucosal barrier predisposes patients to 
infectious complications that can be life-threatening.
Within the GI tract in both GVHD and other inflammatory bow-
el diseases, interleukin 23 (IL-23) has emerged as a pivotal cytokine 
that sits at the apex of a proinflammatory cytokine cascade and is 
directly responsible for the ensuing tissue damage that occurs in 
these disorders (9, 10). Secretion of IL-23 by activated antigen-pre-
senting cells results in widespread inflammatory cytokine produc-
tion as well as activation and expansion of immune effector cell 
populations. Signaling of IL-23 occurs by binding of the cytokine 
to an IL-23 receptor (IL-23R) complex that is composed of IL-12Rβ1 
and a unique IL-23R subunit and is expressed on CD4+ T cells, 
monocytes/macrophages, dendritic cells, and other members 
of the innate immune system (11). Thus, IL-23 is able to mediate 
proinflammatory effects in the GI tract through both the innate and 
adaptive arms of the immune system (10, 12), although the relative 
importance of each component is not completely understood. The 
severity of GVHD is also a function of the balance between effector 
and regulatory arms of the immune system (13, 14). The absence of 
regulatory cell populations has been shown to exacerbate GVHD 
severity (15, 16), indicating that counterregulatory mechanisms are 
operative during GVHD, although often insufficient to prevent or 
mitigate the disease. The precise pathways by which the proinflam-
matory effects of IL-23 are regulated within the colon microenvi-
ronment, however, have not been well delineated.
Herein, we used multiple murine models of GVHD to delin-
eate the specific immune cell populations that mediate the 
proinflammatory effects of IL-23 within the colon and to deter-
mine how inflammation mediated through IL-23/IL-23R signal-
ing was regulated. During the course of these studies, we iden-
tified a novel subset of CD4+IL-23R+ T cells that constitutively 
expresses the β2 integrin CD11c and demonstrated that these 
cells constitute a highly pathogenic CD4+ T cell population that 
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early entry into the GI tract under inflammatory conditions. 
Additionally, we demonstrate that these cells are primarily reg-
ulated by IL-10 that is produced by CD4+ non–Foxp3-express-
ing conventional T cells. Finally, our studies reveal that CD11c 
plays a critical role in colonic inflammation. Moreover, we show 
that this cell population has a biased central memory T cell phe-
notype, a memory T cell transcriptional profile, and increased 
expression of gut-homing molecules, which poises them for 
Figure 1. CD4+IL-23R+ T cells drive inflammation in the colon during GVHD. (A) BALB/c mice were transplanted with B6 BM alone (black circles, n = 12) or 
with B6 spleen cells. Animals transplanted with spleen cells were treated with an isotype control (black squares, n = 20) or anti–IL-23R antibody (white 
squares, n = 20). (B) BALB/c mice transplanted with BM from B6 (black circles, n = 12) or Il23r–/– (white circles, n = 12) donors or BM and spleen cells from B6 
(black squares, n = 17) or Il23r–/– animals (white squares, n = 17). (C) BALB/c mice transplanted with B6 T cell depletion (TCD) BM cells (black circles, n = 9), 
B6 TCD BM plus 0.6 × 106 to 1.2 × 106 purified B6 T cells (black squares, n = 15), B6 TCD BM plus an equivalent number of Il23r–/– T cells (white squares,  
n = 15), or Il23r–/– TCD BM and B6 T cells (white triangles, n = 15). (D) BALB/c mice transplanted with B6 Rag-1 BM (black circles, n = 8) or with CD4+ T 
cells from B6 Il23r+/+ (black squares, n = 14) or Il23r–/– animals (white squares, n = 14). Survival data are from 3–4 experiments per panel. (E) BALB/c mice 
transplanted with B6 Rag-1 BM alone (circles, n = 5) or with purified CD4+ T cells from B6 (squares, n = 7) or Il23r–/– animals (triangles, n = 9). The absolute 
number of CD4+ T cells that secreted IFN-γ and/or IL-17 in the colon 3 weeks after transplantation. (F and G) BALB/c mice transplanted with B6 Rag-1 BM 
and a 1:1 mixture of CD4+ T cells from B6.PL Il23r+/+ and B6 Il23r–/– animals (WT/Il23r–/–) (triangles, n = 7–13), or B6 Rag-1 BM and a mixture of CD4+ T cells 
from B6.PL Il23r+/+ and B6 Il23r+/+ mice (WT/WT) (squares, n = 9–15). Ratio of CD4+ Thy1.1+/Thy1.2+ T cells and absolute number of CD4+Thy1.2+IFN-γ+ and 
Thy1.1+IFN-γ+ T cells is shown. Data in E–G are from 3 experiments. Statistically significant differences were calculated using the log rank test and 2-tailed 
Mann-Whitney U test. *P < 0.05, **P < 0.01, ***P < 0.001.
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ty of animals reconstituted with marrow grafts from wild-type 
donors died from GVHD, mice transplanted with Il23r–/– grafts 
had increased survival (Figure 1B). Histological analysis indicat-
ed that there was reduced inflammation within the colon, but 
no difference in pathological scores in the liver or lung (Supple-
mental Figure 1, A and B; supplemental material available online 
with this article; doi:10.1172/JCI80874DS1), consistent with prior 
observations of preferential protection within this tissue site after 
blockade of IL-23 signaling (9). Prior studies had shown that 
IL-23R gene expression levels were augmented in CD11c+CD11b+ 
cells, CD11c–CD11b+ cells, and CD4+ T cells obtained from the 
colons of mice with GVHD (9), indicating that cells of the innate 
and adaptive arms of the immune system were responsive to IL-23 
signaling. Experiments performed to delineate the critical IL-23R–
is constitutively expressed on human CD4+ T cells and under-
goes increased expression after activation, indicating that this 
phenotype may therefore contribute to the pathophysiology of 
colonic inflammation in humans.
Results
IL-23 mediates GVHD lethality and pathological damage in the colon 
through direct effects on CD4+IL-23R+ donor T cells. To determine 
the functional significance of IL-23R expression on donor cells, 
we used antibody-based and genetic approaches to examine the 
effect of this signaling pathway on GVHD severity. Lethally irradi-
ated recipients treated with anti–IL-23R antibody had significantly 
prolonged survival compared with mice to which control antibody 
was administered (Figure 1A). Similarly, whereas the majori-
Figure 2. CD11b and CD11c expression marks a CD4+IL-23R+ T cell population that accumulates early in the colon early during GVHD. (A) Irradiated BALB/c 
mice were reconstituted with 3 × 106 to 4 × 106 sort-purified B6 CD4+αβ+ T cells. Representative dot plot of IL-23R expression gated on 7-aminoactinomy-
cin–negative (7-AAD–) donor-derived CD4+ T cells from the colon 5 days after transplantation. Staining with an isotype control is shown for comparison. 
IL-23R expression on colonic CD4+ T cells from BALB/c mice transplanted with CD4+ Il23r−/− T cells is shown to confirm antibody specificity. (B) Absolute 
number of CD4+IL-23R+ T cells in the colon of syngeneic (B6.PL→B6) (n = 4) versus allogeneic (B6→BALB/c) (n = 7) recipients. Data are from 2 experiments. 
(C) Representative dot plot of CD11b and CD11c expression on gated 7-AAD− donor-derived CD4+αβ+ T cells isolated from the colon of allogeneic recipients 5 
days after transplantation. (D) Representative dot plot of CD11b and CD11c coexpression on donor-derived CD4+αβ+ T cells from C. (E and F) Percentage and 
absolute number of CD4+IL-23R+ T cells from the 4 quadrants (i.e., R1–R4) depicted in D. Calculations were performed by subtraction of the percentage of 
cells that stained positively for the isotype control from the percentage that were IL-23R+. Data are from 4 experiments (n = 12–13 animals). (G) Irradiated 
B6.PL (n = 4) or BALB/c (n = 12) mice reconstituted with 4 × 106 purified B6 CD4+ T cells. The absolute number of donor CD4+ T cells that expressed CD11b 
and/or CD11c in the colon is shown. Normal nontransplanted (naive) B6 mice (n = 4) served as controls. Data are from 2 experiments. Statistically signifi-
cant differences were calculated using the 2-tailed Mann-Whitney U test. **P < 0.01, ***P < 0.001.
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ate lethal GVHD. Transplantation with CD4+ T cells from Il23r–/– 
animals resulted in less GVHD-associated mortality (Figure 1D) 
and a significant reduction in mRNA levels of the inflammatory 
cytokines IFN-γ, IL-6, and IL-17, but not IL-22 (Supplemental Fig-
ure 1C). The absolute numbers of CD4+, CD4+IFN-γ+, CD4+IL-17+, 
and CD4+IFN-γ+IL-17+ T cells were also significantly reduced in 
the colons of these mice (Figure 1E). We then examined whether 
expressing population revealed that survival was significantly 
prolonged in animals that were transplanted with Il23r–/– T cells, 
whereas mortality was unaffected when IL-23R expression was 
absent from BM-derived cells (Figure 1C), indicating that T cell 
expression of the IL-23R was critical. Since the IL-23R has been 
reported to be expressed on CD4+, but not CD8+, T cells (11), we 
compared the ability of CD4+ Il23r+/+ and Il23r–/– T cells to medi-
Figure 3. β2 Integrin–expressing CD4+ T cells have a biased central memory phenotype and increased expression of gut-homing molecules. (A) Repre-
sentative dot plot depicting CD11b and CD11c expression on gated CD4+TCRβ+ T cells pooled from spleen and lymph nodes (peripheral and mesenteric) of a 
normal B6 mouse. (B) Representative dot plots depicting CD44 and CD62L expression on whole CD4+ T cells, CD4+ T cells that lacked expression of either 
β2 integrin, or CD4
+ T cells that expressed at least 1 of the 2 β2 integrins. (C) Percentage of naive, central memory (CM), and effector memory (EM) CD4+ T 
cells in populations shown in B (n = 5 mice per group). Data are presented as the mean ± SEM. (D) Representative dot plots depicting IL-23R expression 
and background isotype staining on CD4+TCRβ+ T cells, CD4+ T cells that did not express either CD11b or CD11c, or CD4+ T cells that expressed at least 1 of 
these 2 β2 integrins. (E) Scatterplot of percentage of each cell population noted in D that expressed the IL-23R (n = 6 mice per group). (F) Scatterplot of the 
percentage of naive CD4+ T cells lacking expression of either β2 integrin or expressing CD11b alone, CD11c alone, or both CD11b and CD11c (n = 6/group) that 
expressed the IL-23R. (G) Representative histograms and scatterplots of mean fluorescence intensity of CD69, CCR9, and α4β7 expression on CD4+ T cells 
that lacked expression of either β2 integrin or CD4
+ T cells that expressed at least 1 of these 2 integrins. Statistically significant differences were calculated 
using the log rank test and 2-tailed Mann-Whitney U test. **P < 0.01, ***P < 0.001.
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could be identified in the colon of GVHD animals as early as 5 days 
after transplantation (Figure 2A). The specificity of the anti–IL-23R 
antibody was confirmed by demonstration that colonic CD4+ T 
cells obtained from recipients that were reconstituted with CD4+ T 
cells from Il23r−/− mice had no detectable expression of the recep-
tor (Figure 2A). These cells were also present in significantly higher 
numbers in comparison with recipients of syngeneic marrow grafts 
(Figure 2B). Additional phenotypic characterization of CD4+ T cells 
in this tissue site revealed a population of donor-derived CD4+αβ+ 
T cells that expressed the β2 integrins CD11b and CD11c (Figure 
2C). The majority of these cells expressed CD11b alone; however, 
there were defined populations that also expressed CD11c alone or 
both CD11b and CD11c (Figure 2D). To determine whether there 
was any correlation between IL-23R and β2 integrin expression, we 
examined CD4+ T cells from each of these 4 quadrants (i.e., R1–R4) 
for concurrent IL-23R expression. These studies revealed that the 
frequency and absolute number of IL-23R–expressing CD4+ T cells 
CD4+ Il23r–/– T cells were intrinsically defective in their ability to 
accumulate in the colons of animals with GVHD using congenical-
ly marked Il23r+/+ and Il23r–/– T cells. Using Thy1 allelic differences 
to distinguish Thy1.1+ Il23r+/+ from Thy1.2+ Il23r–/– CD4+ T cells, 
we observed that there was no difference in the ratio of Thy1.2+ to 
Thy1.1+ CD4+ T cells (Figure 1F) or the absolute number of Thy1.2+ 
versus Thy1.1+ CD4+ T cells that were capable of secreting IFN-γ 
(Figure 1G) in the colons of transplanted animals. Collectively, 
these studies indicated that the T cell–directed inflammatory 
effects of IL-23 within the colon were mediated primarily by CD4+ 
IL-23R–expressing T cells that were able to drive the accumulation 
and differentiation of Il23r–/– T cells into a proinflammatory phe-
notype through a cell-extrinsic mechanism.
CD4+IL-23R+ T cells in the colon coexpress the β2 integrins CD11b 
and CD11c. The ability of CD4+IL-23R+ T cells to induce inflam-
mation in the colon led us to further characterize these cells. We 
observed that a small population of CD4+IL-23R+ T cells (~1%) 
Figure 4. Pathogenicity of β2 integrin–expressing CD4+ T cells is dependent on the coexpression of the IL-23R. (A and B) BALB/c mice transplanted with  
4 × 106 CD4+αβ+ T cells (circles) (n = 9) or CD4+αβ+CD11b–CD11c– (squares) (n = 8) T cells. Total number of CD4+ (A) and CD4+IL-23R+ T cells (B) in the colon on 
day 5 is shown. Data are cumulative results from 2 experiments. (C) Total number of CD4+IFN-γ+ T cells in the colon on day 10 in mice transplanted with  
1.5 × 106 CD4+αβ+ T cells (circles, n = 10) or CD4+αβ+CD11b–CD11c– T cells (squares, n = 10). Data are from 2 experiments. (D) Pathology scores in the colon 
of mice transplanted with B6 Rag-1 BM alone (circles, n = 8) or together with CD4+αβ+ (squares, n = 15) or CD4+CD11b–CD11c– (triangles, n = 15) T cells 21 
days after transplantation. Data are from 3 experiments. (E) BALB/c mice transplanted with B6 Rag-1 BM alone (black circles, n = 9) or with 1 × 106 sorted 
CD4+αβ+ (black squares, n = 14) or CD4+αβ+CD11b–CD11c– (white squares, n = 14) T cells. Data are from 3 experiments. (F) BALB/c mice transplanted with B6 
Rag-1 BM alone (black circles, n = 9) or with CD4+αβ+ T cells that expressed CD11b+ and/or CD11c+ (black squares, n = 11) or CD4+αβ+CD11b–CD11c– T cells (white 
squares, n = 13). Data are from 3 experiments. (G) BALB/c mice transplanted with B6 Rag-1 BM alone (black circles, n = 7) or with either 1 × 106 CD4+CD11b–
CD11c– T cells (black squares, n = 10), CD4+ T cells that expressed CD11b and/or CD11c (white squares, n = 9), CD4+ Il23r–/– CD11b–CD11c– T cells (black triangles, 
n = 10), or CD4+ Il23r–/– T cells that expressed CD11b and/or CD11c (white triangles, n = 8). Data are from 2 experiments. Statistically significant differences 
were calculated using the log rank test and 2-tailed Mann-Whitney U test. *P < 0.05, **P < 0.01, ***P < 0.001.
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were highest in cells that coexpressed CD11b and CD11c (R3 quad-
rant) (Figure 2, E and F, and Supplemental Figure 2). The absolute 
number of CD4+ T cells that expressed CD11b+ and/or CD11c+ T 
cells was also greater in the colon of recipients that received alloge-
neic marrow grafts when compared with normal mice or recipients 
of syngeneic grafts (Figure 2G), indicating that these cells arose in 
the setting of alloreactivity.
Pathogenicity of β2 integrin–expressing CD4+ T cells is dependent 
on coexpression of the IL-23R. We observed that a small population 
(~8%) of CD4+ T cells obtained from the spleen and lymph nodes 
of normal mice constitutively expressed CD11b and/or CD11c (Fig-
ure 3A). This population was biased toward a CD44hiCD62Lhi cen-
tral memory phenotype when compared with naive CD4+ T cells 
or CD4+ T cells that lacked expression of either β2 integrin (Figure 
Figure 5. CD4+CD11c+ T cells drive inflammation in the colon during GVHD. (A) Baseline IL-23R expression on gated CD4+ T cells from the spleen and lymph 
nodes of normal wild-type, Cd11b−/−, or Cd11c−/− mice. (B and C) BALB/c mice transplanted with B6 Rag-1 BM alone (black circles, n = 9) or with 0.8 × 106 CD4+ 
T cells from wild-type (black squares, n = 15), Cd11b–/– (white squares, n = 15), or Cd11c–/– (white triangles, n = 10) animals. Overall survival and serial weight 
curves are shown. (D) Representative dot plot depicting CD44 and CD62L expression on gated CD4+CD11c+ and CD4+CD11b+ T cells from Cd11b–/– and Cd11c–/– 
animals, respectively. (E) Percentage of CD4+CD11b+ (black bars) and CD4+CD11c+ (white bars) T cells with naive, central memory (CM), or effector memory 
(EM) phenotypes (n = 4). Data are presented as mean ± SEM. (F) Representative histograms of CCR9 and α4β7 expression on CD4+ T cells from Cd11b–/– 
(blue) or Cd11c–/– (pink) mice based on presence (open histograms) or absence (filled histograms) of CD11b or CD11c. Scatterplots of mean fluorescence 
intensity of CCR9 and α4β7 expression on CD4
+ T cells from replicate animals are also depicted. (G) Hierarchical clustering of 684 genes that were signifi-
cantly regulated in flow-sorted CD4+CD11c+CD44hiCD62L+ versus CD4+CD11c–CD44hiCD62L+ T cells from wild-type mice. S1–S3 refer to independent replicate 
samples with each replicate derived from pooled spleen and lymph node cells from 3–4 mice. Z score denotes SD. (H) Waterfall plot showing log2 fold 
difference in gene expression of differentially regulated genes. Red bars denote genes that had increased expression in CD4+CD11c+CD44hiCD62L+ T cells, 
while blue bars depict genes with decreased expression relative to CD4+CD11c−CD44hiCD62L+ T cells. Statistically significant differences were calculated 
using the log rank test and 2-tailed Mann-Whitney U test. *P < 0.05, ***P < 0.001.
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3, B and C), and also had higher expression of the IL-23R (Figure 
3, D and E). Furthermore, IL-23R expression was highest on CD4+ 
T cells that coexpressed both β2 integrins (Figure 3F). Expression 
of the activation molecule CD69, and the gut-homing molecules 
CCR9 and α4β7, was also increased on CD4+ T cells that coexpressed 
CD11b and/or CD11c (Figure 3G). CD11b and CD11c were constitu-
tively expressed on a small percentage of human CD4+ T cells, and 
could be further augmented when cells were stimulated with allo-
geneic peripheral blood mononuclear cells (Supplemental Figure 
3, A and B), indicating that this was not a species-dependent phe-
nomenon. To determine the functional significance of constitutive 
β2 integrin expression on CD4+ T cells, animals were transplanted 
with sorted CD4+αβ+ T cells or CD4+ T cells that lacked expression 
of either CD11b or CD11c. Mice reconstituted with CD4+CD11b− 
CD11c− T cells had a significantly reduced number of total donor-de-
rived CD4+, CD4+IL-23R+, and CD4+IFN-γ+ T cells in the colon (Fig-
ure 4, A–C), indicating that expression of these specific integrins was 
important for the accumulation of proinflammatory CD4+IL-23R+ T 
cells in the colon. Furthermore, we noted that pathological damage 
in the colon was significantly reduced in this cohort (Figure 4D), 
Figure 6. Donor-derived IL-10 regulates GVHD and is produced primarily by non–Foxp3-expressing T cells. (A) BALB/c mice transplanted with BALB/c BM 
and spleen cells (syngeneic) or an equivalent number of B6 BM and spleen cells (allogeneic). Serum cytokine analysis of IFN-γ, IL-10, and IL-17 levels  
(n = 5–9 per group). Data are derived from 2 experiments and presented as mean ± SEM. (B) BALB/c mice transplanted with B6 BM alone (black circles,  
n = 9) or with either wild-type B6 (black squares, n = 14) or B6 Il10–/– (white squares, n = 14) spleen cells. Data are cumulative results from 3 experiments. (C) 
Wild-type BALB/c (black squares, n = 15) or Il10–/– BALB/c (white squares, n = 15) mice transplanted with B6 BM and B6 spleen cells. Wild-type BALB/c mice 
(black circles, n = 9) transplanted with B6 BM cells alone served as controls. Data are cumulative results from 3 experiments. (D) BALB/c mice transplanted 
with B6 Rag-1 BM and B6 10BiT.Foxp3EGFP spleen cells. The absolute number of donor CD4+ (white bars), CD8+ (black bars), and CD4–CD8– (hatched bars) cells 
that were IL-10+ in the specified tissue sites 10 days after transplantation. Data are from 6–12 mice per group from 3 separate experiments. (E) Represen-
tative dot plots depicting the percentage of donor CD4+ and CD8+ T cells that expressed Foxp3 and IL-10 10 days after transplantation. (F and G) Percentage 
and absolute number of CD4+Foxp3+ and CD8+Foxp3+ T cells (Tregs, F) and CD4+Foxp3– and CD8–Foxp3+ T cells (non-Tregs, G) that were IL-10– (white bars) 
or IL-10+ (black bars) (n = 8 per group). Data are presented as mean ± SEM and are from 2 experiments. Statistically significant differences were calculated 
using the log rank test and 2-tailed Mann-Whitney U test. *P < 0.05, **P < 0.01, ***P < 0.001.
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that were supplemented with CD4+ T cells that expressed CD11b 
and/or CD11c, or CD4+ T cells that lacked expression of these cell 
surface molecules. Overall survival was significantly worse in ani-
mals that were reconstituted with CD4+ T cells that expressed at 
and that these animals had significantly prolonged survival relative 
to GVHD control mice reconstituted with whole CD4+ T cells (Fig-
ure 4E). To provide direct evidence that this CD4+ T cell phenotype 
could mediate lethal GVHD, mice were transplanted with BM cells 
Figure 7. GVHD mediated by CD4+IL-23R+ T cells is regulated by IL-10 independently of CD4+Foxp3+ T cells. (A) IL-10 mRNA expression at 3 weeks in colons 
of BALB/c mice transplanted with Rag-1 BM (circles, n = 9) or BM and CD4+ T cells from B6 (squares, n = 14) or Il23r–/– (triangles, n = 15) mice. (B) BALB/c 
animals transplanted with B6 BM (circles, n = 13), B6 BM and spleen cells (squares, n = 15), or Il10–/– BM and Il10–/– spleen cells (diamonds, n = 15). IL-23 
mRNA expression in the colon. (C) BALB/c mice transplanted with Il10–/– BM (black circles, n = 9) or transplanted with Il10–/– spleen cells and treated with 
an isotype (black squares, n = 14) or anti–IL-23R (white squares, n = 14) antibody. (D) BALB/c mice transplanted with Rag-1 BM (black circles, n = 9) or BM 
and CD4+ T cells from B6 (black squares, n = 14), Il23r−/− (white squares, n = 14), Il10−/− (black triangles, n = 14), or Il10−/− Il23r−/− (white triangles, n = 14) T cells. 
(E) BALB/c mice transplanted with Rag-1 BM (black circles, n = 12), or with CD4+IL-10+ and CD8+IL-10+ (black squares, n = 20), CD4+IL-10+ and CD8+IL-10− (white 
squares, n = 20), CD4+IL-10− and CD8+IL-10+ (white triangles, n = 20), or CD4+IL-10− and CD8+IL-10− T cells (black triangles, n = 20). (F) BALB/c animals trans-
planted with B6 BM (white bars) (n = 6) or BM and spleen cells from B6 (black bars) (n = 10) or Il23r–/– (hatched bars) (n = 12) mice. The absolute number of 
CD4+Foxp3+ T cells at 4 weeks. (G) BALB/c mice transplanted with Rag-1 BM (black circles, n = 4) or with CD4+EGFP– T cells (CD4Δ) from Foxp3ΔEGFP animals. 
Mice transplanted with CD4Δ T cells treated with isotype (black squares, n = 11) or anti–IL-23R antibody (white squares, n = 11) weekly for 5 weeks. Data are 
from 3–4 experiments for each panel except G (2 experiments). Significant differences were calculated using the log rank test and 2-tailed Mann-Whitney 
U test. *P < 0.05, ***P < 0.001.
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To further characterize the CD4+CD11c+ T cell population 
from a functional perspective, we observed that there was an 
increased percentage of CD4+CD11c+ as opposed to CD4+CD11c– 
T cells that produced IFN-γ when stimulated in the presence of 
IL-23 (Supplemental Figure 10A). IL-23 did not induce IL-17 in 
either cell population. Additionally, these cells were capable of 
responding to alloantigens in a fashion similar to that of CD4+ 
CD11c–IL-23R– central memory T cells, although proliferation was 
not as robust as observed for naive T cells (Supplemental Figure 
10B). We then performed RNA sequencing (RNA-Seq) analysis on 
sorted CD4+CD11c+ (lacking coexpression of CD11b) and CD4+ 
CD11c− T cells obtained from wild-type mice to define the respec-
tive transcriptional profiles. These studies revealed a total of 587 
differentially expressed genes of which 57 were downregulated 
and 530 were upregulated (Supplemental Figure 11A and Sup-
plemental Table 1). This represented only 2.4% of 21,704 genes 
examined, which is in accord with prior reports of limited dis-
similarity between naive and memory T cells (17). Using gene set 
enrichment analysis on the genes that had increased expression 
in the CD4+CD11c+ group yielded 4 notable annotation clusters by 
Database for Annotation, Visualization and Integrated Discovery 
(DAVID) analysis (Supplemental Table 2). Moreover, we observed 
that a number of genes that are commonly found in memory T 
cells were overexpressed in the CD4+CD11c+ T cell population 
(i.e., H2Ab1, Dusp4, Cd74, Tnfrsf1b, S100a4, Tbet, Klrg1, LgalS3, 
Ifngr1, and CDKn1a) (17) (Supplemental Figure 11B). A limitation 
of this approach, however, was that it compared a population 
with a diverse array of memory T cells with a CD11c+ population 
that was specifically enriched for central memory (CM) T cells. 
Therefore, we performed a more refined analysis to compare 
the respective transcriptional profiles of CD4+ CM T cells based 
on expression or absence of CD11c. This analysis of CD4+ CM T 
cells alone revealed a total of 684 differentially expressed genes of 
which 208 were downregulated and 476 were upregulated (Figure 
5G and Supplemental Table 3). Gene set enrichment analysis of 
overexpressed genes yielded annotation clusters associated with 
antigen processing and immune response, whereas there was only 
1 cluster that emerged in underexpressed genes (i.e., nucleosome) 
(Supplemental Table 4). CD4+CD11c+ CM T cells had increased 
expression of a number of class II genes (H2Aa, H2Eb1, H2Eb2, 
H2DMa, and Cd74) compared with CD4+CD11c– CM T cells (Fig-
ure 5H). Additionally, these T cells had increased expression of 
the gut-homing molecule CCR9, which provided an explanation 
for their preferential ability to mediate inflammation in the GI 
tract. CD4+CD11c+ CM T cells also had expression of genes associ-
ated with the innate immune response (i.e., Tlr7, Tlr12, Nod2, and 
Cd180), as well as genes associated with dendritic cell populations 
(i.e., Cd40, Clec9a, Cxcl16, Siglec), suggesting that these T cells 
also had innate-like qualities. Collectively, these data indicated 
that CD11c expression defined a unique transcriptional profile 
within the CD4+ CM T cell population.
Donor-derived IL-10 regulates IL-23R–mediated GVHD and is 
produced primarily by non–Foxp3-expressing T cells. Since IL-10 has 
been shown to have a critical role in the maintenance of immune 
homeostasis within the colon (18, 19) and, similarly to IL-23, 
also signals through STAT3 (20), we hypothesized that IL-10 
might regulate CD4+ IL-23R–mediated inflammation. Early after 
least 1 of these 2 integrins (Figure 4F). Finally, to determine whether 
the pathogenicity of β2 integrin–expressing CD4+ T cells was depen-
dent on the IL-23R, which was expressed at a higher level on these 
cells (Figure 3, D and F), experiments were performed in which 
animals were transplanted with CD4+ T cells that expressed CD11b 
and/or CD11c from wild-type or Il23r–/– mice. Mice reconstituted 
with CD4+ Il23r−/− T cells that expressed at least 1 β2 integrin had 
significantly greater survival than animals transplanted with CD4+ 
Il23r+/+ T cells that had the same integrin profile (Figure 4G). Thus, 
these data indicated that the pathogenicity of β2 integrin–expressing 
CD4+ T cells was dependent on coexpression of the IL-23R.
CD11c expression on CD4+IL-23R+ T cells defines a colitogenic 
phenotype. To define which β2 integrin was most critical for induc-
ing inflammation and lethality, CD4+ T cells were purified from 
Cd11c−/− or Cd11b−/− mice and transplanted into recipient animals. 
Notably, phenotypic examination prior to transplantation revealed 
that there was no difference in baseline IL-23R expression on 
naive CD4+ T cells from Cd11b−/− or Cd11c−/− mice (Figure 5A). 
Reconstitution with purified CD4+ T cells from Cd11c−/− animals 
resulted in improved survival (Figure 5B) and significantly less 
weight loss (Figure 5C) relative to animals transplanted with wild-
type CD4+ or CD4+ Cd11b−/− T cells, indicating that CD11c expres-
sion on CD4+ T cells was important for in vivo pathogenicity. Ani-
mals reconstituted with CD4+ Cd11c−/− T cells also had reduced 
pathological damage in all tissue sites, although differences were 
most significant in the colon (Supplemental Figure 4, A and B). 
Moreover, there was a significant decrease in the absolute num-
ber of total donor-derived CD4+, CD4+IL-23R+, CD4+IFN-γ+, CD4+ 
T-bet+, and CD4+TNF-α+ T cells in the colon of these mice relative 
to the other cohorts (Supplemental Figure 4, C–F, and Supple-
mental Figure 5, A–D). Similar results were observed in an MHC-
matched, minor antigen–mismatched GVHD model, indicating 
that these results were not strain specific (Supplemental Figure 6, 
A–C). We observed that CD4+ T cells from Cd11c−/− mice did not 
differ from wild-type CD4+ T cells with respect to in vitro prolifera-
tion (Supplemental Figure 7A) or the ability to be polarized into Th1 
or Th2 cytokine phenotypes (Supplemental Figure 7B). Thus, the 
transgenic environment did not alter these specific T cell param-
eters relative to CD4+ T cells from wild-type animals. Phenotypic 
analysis of CD4+CD11b+ and CD4+CD11c+ T cells from Cd11c−/− 
and Cd11b−/− mice, respectively (Supplemental Figure 8), revealed 
that only the latter had a biased central memory phenotype (Fig-
ure 5, D and E), similar to that observed in β2 integrin–expressing 
cells from wild-type animals (Figure 3, B and C). Moreover, the 
IL-23R was expressed only on CD4+CD11c+ T cells with an effector 
or central memory phenotype and not on T cells with a naive phe-
notype (Supplemental Figure 9A). CD4+CD11c+ T cells also had 
increased expression of CCR9 and α4β7 relative to CD4+CD11b+ T 
cells and to CD4+ T cells that lacked expression of either integrin 
(Figure 5F). Notably, CD4+CD11c+ T cells that expressed CCR9 or 
α4β7 had a predominantly effector or central memory phenotype 
(Supplemental Figure 9B). A majority of CD4+CD11c+ T cells also 
expressed CCR7+, with most CCR7-expressing cells having a cen-
tral memory T cell phenotype as well (Supplemental Figure 9B). 
Pathogenic CD4+IL-23R+ T cells were observed to downregulate 
CD62L after trafficking to the colon and had a largely effector 
memory phenotype (Supplemental Figure 9C).
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ed with either an isotype or anti–IL-23R antibody (Figure 7C), indi-
cating that the survival advantage conferred by blockade of IL-23R 
signaling (Figure 1A) was abrogated when donor-derived cells 
were unable to produce IL-10. These results were confirmed using 
a genetic approach that demonstrated that, while animals reconsti-
tuted with CD4+ T cells from Il23r–/– mice had a significant increase 
in survival relative to GVHD control mice, this effect was complete-
ly lost when mice were transplanted with CD4+ T cells from Il10–/– 
Il23r–/– donors (Figure 7D). To determine which IL-10–producing T 
cell population was most important for regulating GVHD lethality, 
experiments were performed in which animals were reconstituted 
with CD4+ and/or CD8+ T cells from either wild-type or Il10–/– mice. 
These studies demonstrated that the accelerated GVHD mortali-
ty observed in the complete absence of donor-derived IL-10 was 
significantly reduced when CD4+IL-10+ T cells were present in 
the marrow graft (Figure 7E). In fact, these mice had survival that 
was not different from that of animals reconstituted with CD4+ 
and CD8+ T cells that were both IL-10 competent. Conversely, 
the presence of CD8+IL-10+ T cells alone had no protective effect, 
even though CD8+ T cells were the predominant IL-10–producing 
population early after transplantation (Figure 6G). Transplantation 
with CD4+ or CD8+ T cells alone from either wild-type or Il10–/– 
mice also confirmed that only CD4+ T cell–derived IL-10 regulated 
GVHD lethality (Supplemental Figure 15).
CD4+Foxp3+ T cells have been shown to regulate GVHD (13), 
and secretion of IL-10 is 1 mechanism by which these cells mitigate 
disease severity (21). Given that IL-10 production by CD4+ T cells 
was critical for reducing GVHD, we sought to determine whether 
this was solely attributable to CD4+Foxp3+ Tregs. We observed that 
there was no difference in the number of CD4+Foxp3+ T cells pres-
ent in the spleen, liver, or lung of animals that were transplanted 
with marrow grafts from wild-type or Il23r–/– donors (Figure 7F). 
We did, however, observe a 2-fold increase in CD4+Foxp3+ T cell 
numbers in the colons of mice transplanted with Il23r–/– grafts. 
Given this increase in Treg numbers within the colon coupled with 
the fact that the survival advantage conferred by IL-23R signaling 
blockade was attributable primarily to protection from colonic 
damage, we examined the requirement for CD4+ Tregs. To address 
this question, purified CD4+ T cells from Foxp3ΔEGFP mice, which 
have a nonfunctional Foxp3 gene, were transplanted along with B6 
Rag-1 BM into lethally irradiated mice, and then treated with either 
an isotype control or anti–IL-23R antibody. Animals to which anti–
IL-23R antibody was administered had significantly prolonged 
survival relative to control mice (Figure 7G), indicating that GVHD 
protection occurring as a consequence of IL-23R signaling block-
ade did not require functional donor-derived CD4+Foxp3+ Tregs, 
and that IL-10 production by non–Foxp3-expressing CD4+ T cells 
was critical for preventing lethality.
Discussion
In the current study, using an experimental model of GVHD to 
examine T cell–mediated inflammation, we have identified a nov-
el subset of CD4+ T cells that constitutively express the β2 integrin 
CD11c, and shown that these cells potently induce inflammation 
in the colon. Notably, we observed that these cells have a biased 
central memory phenotype and transcriptional profile, as well as 
increased expression of the gut-homing molecules CCR9 and α4β7, 
transplantation, we observed that IL-10 levels were significantly 
increased in the serum of recipients of allogeneic as compared 
with syngeneic marrow grafts (Figure 6A), and that this dispari-
ty was relatively sustained during the first 3 weeks in comparison 
with IL-17 and IFN-γ. Donor (Figure 6B) but not host-derived 
IL-10 production (Figure 6C) was critical for mitigating GVHD 
lethality, as recipients of Il10−/− grafts rapidly succumbed to death. 
Given the requirement for donor-derived IL-10, we used 10BiT.
Foxp3EGFP reporter mice to determine which donor cell popula-
tions produced this cytokine. Under steady-state conditions, T 
cells from normal 10BiT.Foxp3EGFP reporter mice produced little 
IL-10 except in the colon, where approximately 70% of CD4+-
Foxp3+ and 15% of CD4+Foxp3− T cells were IL-10+ (Supplemental 
Figure 12, A and B). Notably, fewer than 5% of conventional CD8+ 
T cells produced IL-10 in this tissue. To assess the effect of GVHD 
on IL-10 production, cohorts of animals were transplanted with 
syngeneic or allogeneic marrow grafts from IL-10 reporter mice. 
There were a significantly higher percentage and absolute num-
ber of IL-10+ cells observed in allogeneic recipients compared with 
syngeneic controls (Figure 6, D and E, and Supplemental Figure 
13, A and B). Notably, the preponderance of IL-10 in GVHD target 
tissues derived almost exclusively from donor T cells (Figure 6D). 
In fact, only in the spleen was a significant non–T cell population 
identified that was IL-10+. IL-10 produced by CD4+ and CD8+ T 
cells in GVHD tissues was also detectable by immunoassay, pro-
viding confirmation that T cells were producing actual protein 
(Supplemental Figure 14). CD4+ and CD8+ Foxp3+ Tregs each 
constituted approximately 2%–3% of total CD4+ and CD8+ T cells 
early after transplantation in each organ (Figure 6E), and approx-
imately 50% of these cells expressed IL-10 in mice undergoing 
GVHD. The absolute number of CD8+IL-10+ and CD4+IL-10+ 
Foxp3+ T cells was similar in all tissues, except the liver, where 
there were significantly more CD8+IL-10+ Tregs (Figure 6F). Nota-
bly, there was a substantial percentage of conventional CD4+ and 
CD8+ T cells that produced IL-10 in all organs (Figure 6, E and G). 
While the relative percentage of these cells that were IL-10+ was 
less than that for Foxp3-expressing T cells, the absolute number 
of IL-10–expressing conventional CD4+ and CD8+ T cells was at 
least 10-fold greater (Figure 6G). In addition, CD8+IL-10+Foxp3– 
T cells were present in significantly greater numbers than CD4+ 
IL-10+Foxp3− T cells in all GVHD target organs, including the 
colon, identifying these cells as the major IL-10+ population.
GVHD mediated by CD4+IL-23R+ T cells is regulated by IL-10 inde-
pendently of functional CD4+Foxp3+ T cells. Studies to further exam-
ine the role of IL-10 revealed that mice undergoing GVHD had a 
significant increase in IL-10 gene expression within the colon when 
compared with BM control animals, whereas animals transplant-
ed with CD4+ Il23r–/– T cells had a reduction in IL-10 mRNA levels 
(Figure 7A). Conversely, in the absence of donor-derived IL-10, 
IL-23 levels were increased in comparison with mice transplanted 
with wild-type marrow grafts (Figure 7B), suggesting that IL-10 
production occurred in response to IL-23R–mediated proinflam-
matory effects. To determine whether this premise was correct, we 
examined whether GVHD protection occurring as a consequence 
of IL-23R signaling blockade was dependent on donor-derived 
IL-10. These studies revealed no difference in overall survival 
between animals transplanted with Il10–/– marrow grafts and treat-
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all role for central memory T cells in the induction of GVHD and 
implicate a role for these cells in causing pathological damage 
within the GI tract. Transplantation of stem cell grafts depleted 
of naive T cells has recently been conducted in humans and has 
allowed one to indirectly assess the ability of memory T cells to 
cause GVHD, since these cells are enriched in the depleted stem 
cell product (32). A notable finding from this study was that while a 
majority of patients developed acute GVHD of the GI tract, it tend-
ed to be milder and more responsive to steroids than that observed 
after transplantation with stem cell grafts that also contained naive 
T cells. Thus, while this clinical study did not specifically examine 
central memory CD4+ T cells, this observation is compatible with 
the interpretation that memory T cells may have a proclivity to 
cause inflammation within the intestinal tract in humans as well.
Expression of β2 integrins has been reported on effector CD8+ 
T cells, where this phenotype has been most commonly described 
in viral infections as a marker of recently activated or memory 
cells (33–35). However, the role of β2 integrin–expressing CD4+ 
T cells has not been previously characterized. Known ligands for 
CD11c include ICAM-1, ICAM-2, collagen, and fibrinogen, which 
are all present in the microvasculature (36, 37) and are upregulat-
ed on both endothelial and epithelial cells in the GI tract during 
GVHD (38, 39). Therefore, adherence of CD4+CD11c+ T cells to 
these ligands could serve as a mechanism by which these cells 
enter into the colon and are then able to respond to other inflam-
matory cues that augment their pathogenicity. We observed that 
CD4+CD11c+ T cells from Il23r+/+ mice constituted a small propor-
tion of total splenic and lymph node CD4+ T cells, and that only 
a small percentage CD4+IL-23R+ T cells were detectable in the 
colon, yet these cells were capable of inducing significant patho-
logical damage and mortality. Another explanation for this finding 
emerged from the results of cotransfer experiments that revealed 
equivalent numbers of proinflammatory Il23r+/+ and Il23r–/– T cells 
within the colon of GVHD mice, indicating that CD4+ Il23r–/– T 
cells were capable of expansion and cytokine production in the 
colon, but were dependent on inflammatory signals delivered by 
CD4+IL-23R+ T cells. A similar premise has been advanced in an 
experimental model of inflammatory bowel disease (12). In pre-
vious studies (9), we demonstrated that IFN-γ was an important 
downstream mediator for IL-23–mediated pathological dam-
age within the colon during GVHD. Therefore we surmise that 
increased IFN-γ production as a consequence of the augmented 
number of CD4+ Il23r−/− T cells that accumulate in the presence 
of CD4+IL-23R+ T cells is a primary mechanism by which colonic 
inflammation is promoted.
IL-23 uses STAT3 as a cytoplasmic transcription factor that 
mediates downstream inflammatory events (40), but how this 
cytokine is regulated within the context of colonic inflammation is 
not well defined. Prior studies in murine models of inflammatory 
bowel disease and human colonic biopsies have demonstrated that 
an intact IL-23R signaling pathway is associated with decreased 
production of IL-10 (12, 41), implying that IL-23R signaling sup-
presses antiinflammatory pathways. In contrast to these studies, 
we observed that IL-10 levels in the serum and mRNA levels in the 
colon were significantly increased in mice with GVHD. Moreover, 
mice transplanted with CD4+ Il23r–/– T cells had reduced IL-10 lev-
els within the colon, supporting the premise that IL-10 production 
which facilitated their ability to traffic into the colon microenvi-
ronment. The pathogenicity of these cells was critically dependent 
on coexpression of the IL-23R, which is augmented by the produc-
tion of inflammatory cytokines such as IL-6 and IL-21 (22) that 
are increased in this tissue site during GVHD (23, 24). We initially 
observed that IL-23R expression was increased on CD4+ T cells 
that expressed CD11b and/or CD11c, raising the possibility that 
CD11c served only as a marker for a CD4+ T cell subpopulation that 
expressed the IL-23R, and did not confer additional pathogenic 
properties. However, the fact that baseline IL-23R expression 
was no different on CD4+ T cells from Cd11b−/− and Cd11c−/− ani-
mals, yet the former induced significantly greater mortality and 
pathological damage in the colon, is evidence that CD11c expres-
sion alone is important for in vivo pathogenicity independently of 
IL-23R expression. Thus, our data support a model whereby the 
coordinate expression of CD11c and the IL-23R on CD4+ T cells 
is critical for mediating maximal inflammation within the colon 
(Supplemental Figure 16).
Transcriptional profiling using RNA-Seq demonstrated that 
CD4+CD11c+ T cells from wild-type animals had a profile char-
acterized by increased expression of genes commonly reported 
to be overexpressed in memory T cells (17), providing support for 
the premise that this was a unique central memory–biased CD4+ 
T cell population. Notably, a more refined transcriptional anal-
ysis that examined CD4+CD11c+ versus CD4+CD11c– CM T cells 
revealed that the former T cell population had increased expres-
sion of CCR9, which provided an explanation for why these cells 
are particularly colitogenic. Furthermore, CD4+CD11c+ CM T cells 
also preferentially expressed genes associated with the innate 
immune response and dendritic cell populations, suggesting that 
they have innate-like properties. This would be a potential expla-
nation for how a small population of CD4+ T cells could mediate 
a potent pathogenic effect by recognizing pathogen- or damage- 
associated molecular patterns that could amplify the early donor 
T cell response that we observed within the colon. Whether these 
cells are anatomically restricted to the spleen and lymph nodes 
or recirculate from the GI tract into secondary lymphoid tissues 
is not entirely clear, although the propensity of memory T cells to 
circulate from peripheral to secondary lymphoid tissues is well 
established and seems most plausible (25). Thus, we would posit 
that these cells become primed against self- or bacterial antigens 
in the GI tract and then are able to traffic back to the colon to medi-
ate pathological damage under inflammatory conditions in which 
there are breakdown of mucosal barriers, loss of self-tolerance, 
and re-exposure to gut-associated antigens.
The role of memory T cells in the biology of GVHD has been 
an area of active investigation. A preponderance of preclinical 
studies has indicated that effector memory T cells have a marked-
ly reduced ability to mediate GVHD when compared with naive T 
cells (26–28). The role of central memory T cells in the pathophys-
iology of GVHD, however, has been more controversial, as some 
studies have reported that these cells are able to cause GVHD 
(29, 30), while others have not observed a pathogenic role for this 
cell population (31). Notably, these studies have examined either 
unseparated central memory T cells or central memory CD8+ T 
cells, but have not directly examined the corresponding CD4+ T 
cell population. The results of this study further support an over-
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which blocks the p40 subunit that is shared by IL-12 and IL-23 and 
has been shown to have a role in the pathophysiology of GVHD 
(50). However, given that IL-12 has other critical immunological 
functions (51), the more selective blockade of IL-23 through its 
p19 subunit or unique receptor may be a more rational strategy 
to prevent gastrointestinal GVHD and warrants further inves-
tigation. This would likely be a more effective strategy than one 
directed at attempting to deplete CD11c-expressing CD4+ T cells 
given that this molecule is also expressed on dendritic cell popu-
lations, which could lead to other potentially undesirable effects 
with respect to immune competency and antileukemia reactivity.
In summary, we have identified a novel population of CD4+ 
T cells that constitutively express the β2 integrin CD11c and have 
a biased central memory phenotype and transcriptional profile, 
increased expression of gut-homing molecules, and the ability to 
potently drive inflammation within the colon. These cells also had 
a gene expression profile with both innate and adaptive character-
istics, providing a potential explanation for why these cells play an 
important role in early colonic inflammation. The ability of these 
cells to mediate pathological damage was critically dependent 
on the coordinate expression of the IL-23R in the colon microen-
vironment, which served to further augment inflammation and 
facilitate the expansion of Il23r−/− T cell populations. The role of 
these cells in driving early inflammatory events in colonic GVHD 
suggests that they may have a wider role in the pathogenesis of 
immune-mediated inflammatory bowel diseases in rodents and 
potentially humans.
Methods
Mice. C57BL/6 (B6) (H-2b), BALB/c (H-2d), B6.PL (H-2b, Thy1.1+), 
B6.SJL (CD45.1+), B6 Foxp3EGFP, B6 Rag1–/–, BALB.B (H-2b), Cd11b–/–, B6 
Il10–/–, and BALB/c Il10–/– mice were bred in the Animal Resource Cen-
ter (ARC) at the Medical College of Wisconsin or purchased from The 
Jackson Laboratory. Foxp3ΔEGFP mice, in which there is mutation in the 
Foxp3 coding region that renders the Foxp3 gene nonfunctional, have 
been reported (52). Il23r–/–, Cd11c–/–, and IL-10BiT-Foxp3EGFP reporter 
mice have also been described (53–55). Il23r–/– Il10–/– animals were 
made by intercrossing of Il23r–/– × Il10–/– heterozygotes and screening 
for homozygosity by PCR. All animals were housed in the Association 
for Assessment and Accreditation of Laboratory Animal Care–accred-
ited ARC of the Medical College of Wisconsin. Mice received regular 
mouse chow and acidified tap water ad libitum.
Reagents. Anti–IL-23R antibody is a mouse IgG antibody that has 
been previously described (56). Animals received a dose of 0.75 mg 
i.p. on the day of transplantation prior to irradiation and then were 
treated with 0.75 mg weekly by i.p. injection for 4 additional weeks. 
Mouse IgG (Merck Pharmaceuticals) was used as a control and admin-
istered at the same dose and schedule as anti–IL-23R antibody. Anti-
bodies were resuspended in PBS before injection.
BM transplantation. Bone marrow (BM) was flushed from donor 
femurs and tibias with DMEM (Gibco-BRL) and passed through sterile 
mesh filters to obtain single-cell suspensions. Host mice were condi-
tioned with total-body irradiation administered as a single exposure 
of 900–1,000 cGy at a dose rate of 74 cGy/min using a Shepherd Mark 
I Cesium Irradiator (J.L. Shepherd and Associates). Irradiated recipi-
ents received a single i.v. injection in the lateral tail vein of BM (10 × 
106) with or without added spleen or purified T cells. T cells were puri-
serves as a counterregulatory response to IL-23R–mediated inflam-
mation. The importance of IL-10 as a critical regulatory cytokine of 
IL-23R signaling was corroborated by the fact that transplantation 
with Il10–/– grafts augmented GVHD mortality, blockade of IL-23R 
signaling was ineffectual in the absence of donor-derived IL-10 pro-
duction, and transplantation with CD4+ T cells from Il23r–/– Il10–/– 
animals abrogated the protection that was observed when animals 
were reconstituted with Il23r–/– T cells alone. Thus, a critical role 
of IL-10 appears to be the suppression of inflammation mediated 
by CD4+CD11c+ T cells through the IL-23R signaling pathway. How 
IL-10 directly regulates IL-23 is not entirely clear, although a poten-
tial regulatory pathway may involve Nfil3, an IL-10–inducible gene 
(42) that has been shown to inhibit IL-12/23–mediated colitis in 
immunodeficient animals (43). Therefore, in the absence of IL-10 
production by CD4+ T cells, NFIL3 transcription would be predict-
ed to be decreased, which could lead to enhanced inflammation 
through the IL-23 signaling pathway.
IL-10 production by Tregs has been demonstrated, in a num-
ber of experimental models (44, 45), including GVHD (21, 46), to 
be important for the maintenance of tolerance and the ameliora-
tion of inflammatory responses. Moreover, IL-10 production by 
non–Foxp3-expressing CD4+ T cells, termed Tr1 cells, has also 
been shown to mitigate inflammation in models of autoimmu-
nity and chronic inflammation (47). Although we observed that 
IL-10–expressing Tregs were indeed present in all target tissues, 
the majority of IL-10+ cells were non–Foxp3-expressing T cells, 
primarily CD8+ T cells. Furthermore, blockade of IL-23R signal-
ing was able to prolong survival in the complete absence of CD4+ 
Tregs, indicating that, in contrast to IL-10, there was not a strict 
requirement for Tregs to observe a protective effect from IL-23R 
signaling inhibition. T cell subset transfer studies designed to 
determine the T cell population that was critical for the produc-
tion of IL-10 and amelioration of GVHD severity revealed that 
non–Foxp3-expressing CD4+ T cells were actually most responsi-
ble for the mitigation of GVHD. Notably, CD4+ T cells obtained 
from GVHD target tissues also produced higher levels of IL-10 
in vitro than the corresponding CD8+ T cell population, provid-
ing an explanation for why these cells might be more potent in 
vivo. Thus, while non–Foxp3-expressing CD8+IL-10+ T cells have 
been shown to exert a dominant suppressive role in other settings 
(48), they did not mediate any apparent protective effect, despite 
being present in significantly higher absolute numbers in all tissue 
sites. An explanation for these results is that the 10BiT.Foxp3EGFP 
reporter mouse quantifies not the amount of IL-10 produced, but 
rather only the percentage of cells that have been programmed to 
make IL-10. Therefore, our data would support the interpretation 
that non–Foxp3-expressing CD4+ T cells produced more IL-10 
on a per-cell basis. While these results do not exclude a role for 
Treg-derived IL-10 in GVHD prevention, by either donor or resid-
ual radioresistant recipient populations, they indicate that IL-10 
production by non–Foxp3-expressing CD4+ T cells appeared to be 
critical for the regulation of colonic inflammation in this setting.
From a clinical perspective, blockade of the IL-23 signaling 
pathway is a potentially viable strategy to reduce the severity of 
GVHD in the GI tract, which remains a major cause of morbidity 
in allogeneic hematopoietic stem cell transplant recipients. Anec-
dotal reports (49) have demonstrated activity of ustekinumab, 
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to the manufacturer’s instructions. In brief, sorted CD4+ or CD8+ T 
cells were activated with PMA/ionomycin plus 30 U/ml of IL-2 over-
night. Supernatants were harvested from activated T cell cultures, and 
murine IL-10 was detected using magnetically coupled anti–IL-10 
beads, biotinylated detection antibodies, and a reporter streptavi-
din-phycoerythrin conjugate. Data were collected and analyzed using 
a Bio-Plex 200 instrument equipped with BioManager 6.0 analysis 
software (Bio-Rad Laboratories).
Human mixed lymphocyte cultures. Mixed lymphocyte cultures 
were performed using peripheral blood mononuclear cells (PBMCs) 
obtained from healthy blood donor buffy coat units after density gra-
dient separation (Biocoll; Merck Millipore). Peripheral blood lympho-
cytes were prepared from PBMCs by incubation in T25 flasks at 37°C 
for 4 hours to overnight and removal of nonadherent cells. Peripheral 
blood lymphocyte responders were cultured in RPMI-1640 (25 mM 
HEPES/2 mM l-glutamine)/10% single-donor human AB serum 
(GemCell; Gemini Bio-Products) and were admixed at a 1:1 ratio with 
30-Gy-irradiated PBMCs from a fully allogeneic donor. A total of 10 
ml of the cell mixture was incubated at 37°C in T25 tissue culture flasks 
in a humidified atmosphere of 5% CO2 for a period of 7–8 days. After 
incubation, cells were washed from culture, centrifuged over density 
gradient medium, and phenotyped for the expression of CD11b and 
CD11c on CD3+CD4+ T cells. Nonstimulated control cells were pheno-
typed before incubation.
Histological analysis. Representative samples of liver, colon, and 
lung were obtained from transplanted recipients and fixed in 10% 
neutral-buffered formalin. Samples were then embedded in paraffin, 
cut into 5-μm-thick sections, and stained with H&E. A semiquantita-
tive scoring system was used to account for histological changes in the 
colon, liver, and lung as previously described (9, 23). All slides were 
coded and read in a blinded fashion. Images were visualized with an 
Olympus BX45 microscope. Image acquisition was performed with an 
Olympus DP70 digital camera and software package.
RNA isolation, cDNA synthesis, and real-time quantitative PCR. 
Total RNA was homogenized from flash-frozen tissues collected 
from transplant recipients using Trizol Reagent (Life Technologies) 
followed by isopropyl alcohol precipitation. cDNA was synthesized 
using the QuantiTect Reverse Transcription Kit (Qiagen) according to 
the manufacturer’s protocol. Real-time quantitative RT-PCR was per-
formed using QuantiFast SYBR Green PCR Kit (Qiagen) and run in a 
CFX C1000 Real-Time Thermal Cycler (Bio-Rad Laboratories). The 
18S reference gene was amplified using the QuantiTect Primer Assay 
Kit (Qiagen). The primers for IL-23 (forward 5′-AGCGGGACATAT-
GAATCTACTAAGAGA-3′, reverse 5′-GTCCTAGTAGGGAGGTGT-
GAAGTTG-3′) and IL-10 (forward 5′-ATGCTGCCTGCTCTTACT-
GACTG-3′, reverse 5′-CCCAAGTAACCCTTAAAGTCCTGC-3′) 
were purchased from Integrated DNA Technologies. Specificity for all 
quantitative RT-PCR reactions was verified by melting curve analysis. 
To calculate fold change in gene expression, the average ΔΔCt values 
from triplicate wells were combined from separate experiments.
RNA sequence analysis. RNA was extracted from flow-sorted 
CD4+CD11c− (2.6 × 106 to 3.2 × 106) or CD4+CD11c+ (2.75 × 104 to 4.25 
× 104) T cells using the RNeasy Mini Kit (Qiagen), and mRNA sequenc-
ing libraries were prepared according to the TruSeq protocol (Illumi-
na). For mRNA sequencing, samples were processed as previously 
described by the Cancer Genome Atlas (57) and sequenced on 1 lane of 
an Illumina HiSeq2500 with 2 × 50 paired-end sequencing chemistry. 
fied by magnetic beads using a pan–T cell isolation column (Miltenyi 
Biotec), or by cell sorting. Mice were weighed 2–3 times per week and 
were euthanized when they attained predefined morbidity criteria. 
In experiments that used Foxp3ΔEGFP mice as donors, CD45.2+CD4+ 
EGFP– T cells were sorted from the spleens of reconstituted animals 
before transplantation.
Isolation of lymphocyte populations. Lamina propria lymphocytes 
were isolated from colon samples using the Lamina Propria Dissocia-
tion Kit (Miltenyi Biotec) according to the manufacturer’s instructions. 
The resulting cell suspension was then layered on a 44%/67% Percoll 
gradient (Sigma-Aldrich). Liver and lung lymphocytes were isolated 
by collagenase D digestion followed by layering on a Percoll gradient.
Cell sorting and flow cytometry. Spleen and peripheral lymph node 
cells from mice were sorted on a FACSAria (Becton Dickinson). Lym-
phocytes from spleen, liver, colon, and lung were labeled with mAbs 
conjugated to fluorescent dyes as listed in Supplemental Table 5. 
7-Aminoactinomycin was used to exclude dead cells. Cells were ana-
lyzed on a BD LSRII flow cytometer with FACSDiva software (Becton 
Dickinson). Data were analyzed using FlowJo software (Tree Star).
T cell proliferation and polarization assays. For proliferation experi-
ments, naive CD4+CD62L+CD44− spleen cells were sorted and loaded 
with Cell Trace Violet dye (Invitrogen). Cells were then cultured for 3 
days in complete DMEM supplemented with 10% FBS (Atlanta Biolog-
icals), 1× penicillin/streptomycin/glutamine, 1× nonessential amino 
acids, 1× sodium pyruvate, 10 mM HEPES, 50 μM 2-mercaptoethanol 
(Invitrogen), 1 μg/ml anti-CD28 antibody (BD Pharmingen), and 20 U 
human IL-2 in a flat-bottom 96-well plate coated with 5 μg/ml anti-
CD3 antibody (BD Pharmingen). For cell polarization studies, naive 
spleen cells were cultured in anti-CD3 antibody–coated flat-bottom 
96-well plates in complete DMEM containing anti-CD28 antibody 
and IL-2 with either 20 ng/ml IL-12 and 10 ng/ml anti–IL-4 antibody 
(Biolegend) (Th1 conditions), or 100 ng/ml IL-4 (Shenandoah Bio-
technology), 10 ng/ml anti–IFN-γ antibody (BD Biosciences), and 10 
ng/ml anti–IL-12 antibody (Biolegend) (Th2 conditions). Cells were 
cultured for 48 hours, at which point they were transferred to a new 
plate and cultured for an additional 3 days. On day 5, cells were stained 
for intracellular IFN-γ and IL-4.
Mixed lymphocyte culture. Sorted CD4+ T cell populations (2.5 × 
104 to 3 × 104) were labeled with Cell Trace Violet and then cocultured 
with 1.5 × 104 BALB/c dendritic cell–enriched stimulator cells in V-bot-
tomed microwell plates (Becton Dickinson) at 37°C for 4 days. Stim-
ulator cells were obtained by digestion of spleens with collagenase D 
(1 mg/ml) followed by positive selection of CD11c+ cells using the 
magnetic activated cell sorting system.
Serum cytokine measurements. Serum was collected from mice by 
retro-orbital bleeds and analyzed using a Bio-Plex System (Bio-Rad 
Laboratories) according to the manufacturer’s instructions.
Intracellular cytokine staining. Lymphocytes isolated from the colon 
were stimulated with 50 ng/ml phorbol 12-myristate 13-acetate (PMA; 
Sigma-Aldrich) and 750 ng/ml ionomycin (Calbiochem) for 1 hour and 
then incubated with GolgiStop (BD Pharmingen) for an additional 4 
hours. In other experiments, splenic T cells were stimulated with PMA 
and ionomycin plus IL-23 (20 ng/ml) overnight and incubated with 
GolgiStop for a total of 18 hours. Cells were surface stained and then 
intracellularly stained with mAbs listed in Supplemental Table 5.
Immunoassay. IL-10 was measured using the quantitative Bio-
Plex Mouse Cytokine IL-10 assay (Bio-Rad Laboratories) according 
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Statistics. Group comparisons of T cell populations, cytokine levels, 
pathology scores, and gene expression data were performed using the 
nonparametric 2-tailed Mann-Whitney U test. Survival curves were con-
structed using the Kaplan-Meier product limit estimator and compared 
using the log rank rest. A P value of ≤0.05 was considered significant.
Study approval. All experiments were reviewed and approved by 
the Institutional Animal Care and Use Committee of the Medical Col-
lege of Wisconsin (Milwaukee, Wisconsin, USA).
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Bases and quality control assessment of sequencing were generated 
by CASAVA 1.8 (Illumina). Quality control-passed reads were aligned 
to the mouse reference genome using MapSplice (58). Aligned reads 
were sorted and indexed using SAMtools (http://www.htslib.org), and 
then translated to transcriptome coordinates and filtered for large 
inserts and zero mapping quality using UBU 1.0 (https://github.com/
mozack/ubu). For the reference transcriptome, University of Cal-
ifornia, Santa Cruz, mouse Known Genes (59) was used, with genes 
located on nonstandard chromosomes removed. The abundance of 
transcripts was then estimated using an Expectation-Maximization 
algorithm implemented in the software package RSEM 1.1.13 (60). 
Estimated counts were normalized to the upper quartile (61) before 
comparison of expression across protocols. Genes were tested for 
significant differences in expression between groups using Welch’s t 
tests with Bonferroni correction for multiple testing, implemented in 
the multtest R package (Team RDC, 2011; ref. 62). Significantly dif-
ferentially expressed genes were taken to be those for which the Bon-
ferroni-adjusted P value was less than 0.05, and expression values of 
these genes were displayed as a heatmap made using the heatmap.2 
function in the gplots R package, with cluster method “complete” and 
distance method “Euclidean” (Team RDC, 2011; ref. 63).
Gene set enrichment analysis. Differentially expressed genes were 
tested for gene set and pathway enrichment using the DAVID soft-
ware tool (64, 65). GOTERM_BP_FAT (gene ontology), KEGG (path-
ways), and INTERPRO (protein domains) were used as search terms. 
Significance was defined as P value adjusted by FDR of less than or 
equal to 0.05.
Accession numbers. Accession numbers are as follows: CD11c+ P1 
(GSM2209500); CD11c+ P2 (GSM2209501); CD11c+ P3 (GSM2209502); 
CD11c– P1 (GSM2209503); CD11c– P2 (GSM2209504); CD11c– P3 
(GSM2209505).
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